Cargando…
Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial
BACKGROUND: No specific antiviral drug has been proven effective for treatment of patients with severe coronavirus disease 2019 (COVID-19). Remdesivir (GS-5734), a nucleoside analogue prodrug, has inhibitory effects on pathogenic animal and human coronaviruses, including severe acute respiratory syn...
Autores principales: | Wang, Yeming, Zhang, Dingyu, Du, Guanhua, Du, Ronghui, Zhao, Jianping, Jin, Yang, Fu, Shouzhi, Gao, Ling, Cheng, Zhenshun, Lu, Qiaofa, Hu, Yi, Luo, Guangwei, Wang, Ke, Lu, Yang, Li, Huadong, Wang, Shuzhen, Ruan, Shunan, Yang, Chengqing, Mei, Chunlin, Wang, Yi, Ding, Dan, Wu, Feng, Tang, Xin, Ye, Xianzhi, Ye, Yingchun, Liu, Bing, Yang, Jie, Yin, Wen, Wang, Aili, Fan, Guohui, Zhou, Fei, Liu, Zhibo, Gu, Xiaoying, Xu, Jiuyang, Shang, Lianhan, Zhang, Yi, Cao, Lianjun, Guo, Tingting, Wan, Yan, Qin, Hong, Jiang, Yushen, Jaki, Thomas, Hayden, Frederick G, Horby, Peter W, Cao, Bin, Wang, Chen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7190303/ https://www.ncbi.nlm.nih.gov/pubmed/32423584 http://dx.doi.org/10.1016/S0140-6736(20)31022-9 |
Ejemplares similares
-
Evaluation of the efficacy and safety of intravenous remdesivir in adult patients with severe COVID-19: study protocol for a phase 3 randomized, double-blind, placebo-controlled, multicentre trial
por: Wang, Yeming, et al.
Publicado: (2020) -
Risk Factors of Viral RNAaemia and Its Association With Clinical Prognosis Among Patients With Severe COVID-19
por: Li, Hui, et al.
Publicado: (2021) -
The Efficacy and Safety of Janus Kinase Inhibitors for Patients With COVID-19: A Living Systematic Review and Meta-Analysis
por: Zhang, Xueyang, et al.
Publicado: (2022) -
On the use of corticosteroids for 2019-nCoV pneumonia
por: Shang, Lianhan, et al.
Publicado: (2020) -
Association of acute kidney injury with 1-year outcome of kidney function in hospital survivors with COVID-19: A cohort study
por: Gu, Xiaoying, et al.
Publicado: (2022)